Trade Secrets

Secrecy or Monopoly: What Kewanee Oil v. Bicron Still Teaches About the Patent–Trade-Secret Choice

A half-century after the Supreme Court blessed trade secrets, Kewanee Oil v. Bicron remains the clearest map of when to file and when to keep quiet.

February 3, 2026
A locked vault door beside a stamped patent certificate
The strategic fork every innovator faces: disclose and claim a term-limited monopoly, or keep the formula behind the vault door. Shutterstock
Educational content, not legal advice. This article explains general legal concepts. It does not create an attorney–client relationship. For your specific situation, consult a licensed attorney.

In Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470 (1974), the Supreme Court of the United States — Chief Justice Burger writing for a six-Justice majority, argued January 9, 1974 and decided May 13, 1974, No. 73-187 — answered a question that had split the circuits and that still frames every modern conversation about how to protect a valuable idea: does federal patent law preempt state trade-secret law, or can the two regimes coexist? The Court held they coexist. State trade-secret protection survives, even for subject matter that could have been patented. The decision did not merely settle a doctrinal turf war; it ratified the strategic choice at the heart of intellectual property practice — the choice between disclosure for a fixed monopoly and secrecy for an indefinite, fragile head start.

The facts make the stakes concrete. Harshaw Chemical Company, a division of Kewanee Oil, had spent more than a million dollars and the better part of two decades developing processes for growing synthetic crystals used to detect ionizing radiation. In 1966 it achieved what the industry had thought impossible: a seventeen-inch crystal. The manufacturing know-how behind that breakthrough was never patented; it was held as a trade secret. Former Harshaw employees who had signed confidentiality agreements left, formed Bicron, and produced a competing seventeen-inch crystal by April 1970. The District Court for the Northern District of Ohio applied Ohio trade-secret law and enjoined the use or disclosure of twenty of the forty asserted secrets. The Sixth Circuit affirmed the factual findings but reversed on preemption, reasoning that Ohio law collided with the federal patent statutes. The Supreme Court reversed the Sixth Circuit and restored the protection.

At a glance

  • Case: Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470 (1974), No. 73-187 (argued Jan. 9, 1974; decided May 13, 1974).
  • Holding: State trade-secret law is not preempted by federal patent law; the two regimes serve different functions and coexist.
  • Vote: 6–2 (Burger, C.J., for the Court; Marshall, J., concurring in the result; Douglas, J., dissenting, joined by Brennan, J.; Powell, J., not participating).
  • Why it matters: It confirmed that an innovator may lawfully choose secrecy over a patent — and supplied the still-governing framework for when that choice is rational.
  • The enduring tension: Trade-secret protection can last forever but evaporates on independent discovery or reverse engineering; a patent is robust but term-limited and demands full public disclosure.

The strategic choice the Court was forced to confront

The Sixth Circuit’s preemption theory rested on a clean intuition: the patent bargain is disclosure in exchange for a limited monopoly, and any state law that lets an inventor keep a patentable invention secret undercuts the federal policy favoring disclosure. If trade-secret law lets you hoard what the patent system wants published, the argument runs, it must yield.

The majority dismantled that intuition by sorting inventions into three categories and asking, for each, whether trade-secret protection actually deters patenting. For inventions that are clearly patentable, the Court found the risk that an inventor would choose secrecy “remote indeed.” Trade-secret law, Burger emphasized, offers far weaker protection than a patent: it does not bar independent creation or reverse engineering, and the holder lives under the constant threat that a competitor will simply figure it out. A rational actor holding a strong, durable invention will almost always prefer the seventeen-year monopoly (the term then in force) to that precarious secrecy. For inventions of doubtful patentability — the vast middle — trade-secret protection is affirmatively useful: without it, firms would fracture their research, restrict knowledge to a handful of trusted insiders, and forgo licensing, all to the detriment of innovation. For inventions that are clearly unpatentable, there is no patent to forgo, so abolishing trade-secret law would buy the public no additional disclosure at all.

That tripartite analysis is the case’s lasting contribution to strategy. It reframes the patent-versus-secret decision not as a moral preference for openness but as a portfolio problem: match the protection regime to the character of the asset.

The disclosure–exclusivity tradeoff, made explicit

What Kewanee tacitly endorsed, the Second Circuit had already articulated with characteristic bluntness a generation earlier. In Metallizing Engineering Co. v. Kenyon Bearing & Auto Parts Co., 153 F.2d 516 (2d Cir. Jan. 10, 1946), Judge Learned Hand confronted an inventor who had commercially exploited a secret metal-conditioning process for years before filing, and held the patent forfeited. The inventor, Hand wrote, “must content himself with either secrecy, or legal monopoly.” He cannot have both — cannot bank years of secret commercial profit and then claim the full patent term on top of it.

That is the disclosure–exclusivity tradeoff in its starkest form. The patent system offers exclusivity but conditions it on prompt, full public disclosure; the trade-secret system offers indefinite duration but conditions it on continuing secrecy and tolerates lawful reverse engineering. Kewanee confirms you may pick either path. Metallizing confirms you cannot straddle them: secretly commercializing first and patenting later is the one move the system forecloses, because it would extend the effective monopoly beyond what Congress allowed.

For the strategist, the lesson is sequencing. The decision to keep something secret is, in practical effect, a decision to abandon the patent — and the abandonment may become irreversible the moment commercial exploitation begins. The clock is not the one-year grace period alone; it is the forfeiture principle that converts secret commercial use into a permanent bar.

How the on-sale bar still polices the boundary

The forfeiture logic of Metallizing did not fade with the 1952 Act or the America Invents Act. In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123 (2019), No. 17-1229 (argued Dec. 4, 2018; decided Jan. 22, 2019), a unanimous Supreme Court held that the AIA’s “on sale” bar reaches secret sales — a commercial sale to a third party bound by confidentiality can still invalidate a later patent. Helsinn had licensed its anti-nausea drug to a distributor under a confidentiality obligation more than a year before filing; that confidential commercial transaction was enough to start the bar running.

Helsinn matters to the patent-versus-secret strategist because it confirms the boundary Kewanee presupposed. You can keep your invention secret and protect it under state law indefinitely. But the moment you treat it as a commercial product — selling it, or even confidentially licensing it for sale — you have started the patent clock, and once that clock runs out the patent door closes for good. The two regimes are alternatives precisely because the law refuses to let confidential commercialization buy a fresh patent term.

Open questions

Kewanee answered the preemption question, but it left the strategic frontier unsettled in ways that still generate litigation:

  • How durable is the secret? The Court assumed reverse engineering and independent discovery are real risks. Where a process leaves no trace in the product — as in Metallizing — secrecy can outlast any patent. Where the product is self-disclosing, secrecy may be illusory, and a patent the only real protection.
  • Does the federal trade-secret cause of action (the Defend Trade Secrets Act of 2016) change the calculus? Kewanee analyzed state law under a Supremacy Clause lens. A federal misappropriation remedy strengthens the secrecy path but raises fresh questions about the interaction between two federal IP statutes that Kewanee’s preemption framework was not built to resolve.
  • Where is the line between lawful reverse engineering and misappropriation in a world of data, software, and AI models? The crystal-growing know-how in Kewanee was a classic manufacturing process. Modern secrets — weights, training data, algorithms — test whether “independent discovery” remains a meaningful safety valve.

Implications

  • Treat the choice as asset-specific, not ideological. Use Kewanee’s three categories: patent the clearly patentable and self-disclosing; consider secrecy for the doubtful, the process-embedded, and the clearly unpatentable.
  • Decide before you commercialize. Metallizing and Helsinn make secret commercial use a one-way door — it can forfeit the patent right you might later want. Resolve the question before the first confidential sale or license.
  • Do not assume you can do both. Years of quiet commercial exploitation followed by a patent filing is the precise sequence the forfeiture and on-sale doctrines exist to defeat.
  • Invest in the secrecy infrastructure. Confidentiality agreements were decisive in Kewanee; the protection is only as strong as the reasonable measures that sustain it.
  • Reassess durability honestly. Secrecy’s indefinite term is worthless if the invention is one teardown away from being copied; in that posture, the term-limited patent is the stronger asset.

Frequently asked questions

Did Kewanee hold that trade secrets are always preferable to patents? No. It held only that state trade-secret law is not preempted, so the choice is legally available. The Court in fact predicted that holders of strong, clearly patentable inventions would usually prefer patents, because trade-secret protection is weaker against reverse engineering and independent discovery.

Can I keep an invention secret for years and then patent it? Generally no. Under Metallizing Engineering Co. v. Kenyon Bearing (2d Cir. 1946) and Helsinn v. Teva (2019), secret commercial use or a confidential sale more than the statutory period before filing can forfeit or bar the patent. Secret commercialization and a later patent are largely incompatible.

Is Kewanee still good law after the 2016 Defend Trade Secrets Act? Yes. The DTSA created a federal civil cause of action for misappropriation but did not displace state trade-secret law or disturb Kewanee’s holding that patent law does not preempt trade-secret protection. The decision remains the foundational authority on the coexistence of the two regimes.

Authorities and sources